-- On-track to nominate development candidate
in 2024 --
BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology,
Inc. (Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical needs, today announced new preclinical data demonstrating
proof-of-concept for its differentiated HER3-ADC program. The
data will be presented in a poster session at the American
Association for Cancer Research (AACR) Annual Meeting 2024, being
held April 5-10 in San Diego, California.
"We are pleased to share the first preclinical proof-of-concept
data for our HER3-ADC program, reinforcing our commitment to
advancing a portfolio of differentiated ADC-based therapies that
may deliver better outcomes for patients," said David Dornan, Ph.D., Chief Scientific Officer of
Elevation Oncology. "With our HER3-ADC program, we set out to
design a differentiated ADC which selectively binds to HER3 and is
internalized to potentially attack HER3-expressing cancerous cells
while minimizing systemic exposure. Preclinical data with our
proof-of-concept HER3-ADC shows HER3-dependent cell killing and
robust anti-tumor activity in vivo where HER3 is expressed
at high levels. We look forward to nominating a development
candidate from our HER3 program later this year and, subsequently,
advancing our program closer to the clinic."
HER3 is a clinically validated oncology and antibody-drug
conjugate (ADC) target, which is overexpressed in a range of solid
tumors, including breast cancer, EGFR-mutant non-small cell lung
cancer and pancreatic cancer, and is often associated with poor
clinical outcomes. Elevation Oncology's HER3-ADC program conjugated
seribantumab, its anti-HER3 monoclonal antibody, with a cleavable
valine-citrulline linker and monomethyl auristatin E (MMAE) payload
to yield HER3-ADC1, a proof-of-concept molecule with an average
drug-antibody ratio (DAR) of 4.
In a poster titled, "Therapeutic potential of a HER3
antibody-drug conjugate for the treatment of HER3-expressing
cancers," Elevation Oncology scientists presented in vitro
and in vivo data of a seribantumab-based ADC for patients
with HER3-expressing cancers. The data showed:
- HER3-ADC1 binding to cancer cells, endocytosis, MMAE release
and inhibition of proliferation were dependent on HER3
expression.
- In cytotoxicity assays, HER3-ADC1 displayed HER3-dependent cell
killing and outperformed a benchmark HER3-ADC with a deruxtecan
payload, which is currently in clinical development.
- In a patient derived xenograft (PDX) model of pancreatic cancer
with high HER3 expression, HER3-ADC1 induced tumor regression,
whereas an isotype-MMAE control and a benchmark HER3-ADC with a
deruxtecan payload had only a modest effect.
The poster presentation is now available in the "Publications"
section of Elevation Oncology's website:
https://elevationoncology.com/resources/publications/.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on
the discovery and development of selective cancer therapies to
treat patients across a range of solid tumors with significant
unmet medical needs. We are leveraging our antibody-drug conjugate
(ADC) expertise to advance a novel pipeline, initially targeting
two clinically validated targets in oncology, Claudin 18.2 and
HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC
designed to target Claudin 18.2 and is currently being evaluated in
a Phase 1 trial (NCT05980416) in patients with advanced,
unresectable or metastatic solid tumors likely to express Claudin
18.2 including gastric, gastroesophageal junction, pancreatic or
esophageal cancers. Additionally, we expect to nominate a
development candidate for our second program, a HER3-targeting ADC
for the treatment of patients with solid tumors that overexpress
HER3, in 2024. For more information, visit
www.ElevationOncology.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, anticipated clinical and preclinical development
activities, expected timing of announcements regarding development
activities, potential benefits of Elevation Oncology's product
candidates, potential market opportunities for Elevation Oncology's
product candidates and the ability of Elevation Oncology's product
candidates to treat their targeted indications. All statements
other than statements of historical fact are statements that could
be deemed forward-looking statements. These forward-looking
statements may be accompanied by such words as "aim," "anticipate,"
"believe," "could," "estimate," "expect," "forecast," "goal,"
"intend," "may," "might," "plan," "possible," "potential," "will,"
"would," and other words and terms of similar meaning. Although
Elevation Oncology believes that the expectations reflected in such
forward-looking statements are reasonable, Elevation Oncology
cannot guarantee future events, results, actions, levels of
activity, performance or achievements, and the timing and results
of biotechnology development and potential regulatory approval are
inherently uncertain. Forward-looking statements are subject to
risks and uncertainties that may cause Elevation Oncology's actual
activities or results to differ significantly from those expressed
in any forward-looking statement, including risks and uncertainties
related to Elevation Oncology's ability to advance its product
candidates, the timing and results of preclinical studies and
clinical trials, approvals and commercialization of product
candidates, the receipt and timing of potential regulatory
designations, Elevation Oncology's ability to fund development
activities and achieve development goals, Elevation Oncology's
ability to protect intellectual property, Elevation Oncology's
ability to establish and maintain collaborations with third
parties, and other risks and uncertainties described under the
heading "Risk Factors" in documents Elevation Oncology files from
time to time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and Elevation Oncology undertakes no obligation to revise
or update any forward-looking statements to reflect events or
circumstances after the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-presents-preclinical-proof-of-concept-data-for-her3-adc-program-at-aacr-annual-meeting-2024-302109511.html
SOURCE Elevation Oncology